The HSI opened 102 pts higher before briefly turning south, but later regained upward momentum. It closed the day at 26,009, up 124 pts or 0.48%, with full-day turnover reaching HKD255.179 billion. The HSTECH closed at 4,875, up 46 pts or 0.96%, while the HSCEI closed at 8,652, up 40 pts or 0.46%.

Dotcom bellwethers drove the broader market higher. BABA-W (09988.HK) had a good run, closing at HKD125.2, up 7.01%, after launching the Qwen 3.8-Max AI model, with performance comparable to Anthropic Fable. TENCENT (00700.HK), BIDU-SW (09888.HK) and KUAISHOU-W (01024.HK) soared more than 3%. JD-SW (09618.HK) and MEITUAN-W (03690.HK) gained more than 1%. XIAOMI-W (01810.HK) bucked the trend, down 2.85%, after announcing price increases of up to RMB500 for premium smartphone models. UBS lowered its TP on the company, citing persistently high memory costs and weak end-market demand.

China's State Administration for Market Regulation (SAMR) launched price compliance guidance for the photovoltaic industry, boosting solar stocks. XINYI SOLAR (00968.HK) was the best-performing blue chip of the day, jumping up 13.41%. Following its results announcement, Citi upgraded the stock to Buy. GCL TECH (03800.HK) spiked 11.48%, while FLAT GLASS (06865.HK) climbed 11.22%.

Autos were in a mixed bag. LI AUTO-W (02015.HK) fell off 2.92%, while GEELY AUTO (00175.HK) declined 1.11%. BYD COMPANY (01211.HK) edged up 0.8%. Metal and resource stocks came under pressure, with CHINAHONGQIAO (01378.HK) retreating 6.44% and CHALCO (02600.HK) dropping 2.36%. PETROCHINA (00857.HK) and SINOPEC CORP (00386.HK) both lost more than 1%.
~

AASTOCKS Financial News
Website: www.aastocks.com

CMSI said in a report that cloud business growth in the US internet sector has returned to an upward trajectory, while fundamentals of core businesses remain solid. Returns from AI investment are being realized through incremental cloud backlog orders and gains from equity investments.

The report said overall free cash flow in the sector remains under pressure, while capital expenditure guidance has diverged. Meta Platforms, Inc. (META.US) has become more cautious in its investment pace and is shifting toward enterprise AI business deployment, while the other three tech giants continue to signal increased investment.

Growth at the three major cloud platforms accelerated again, and AI investment has begun converting into revenue and order backlog. The broker remains positive on the US internet sector, with stock preference ranking unchanged: Meta Platforms, Inc. (META.US) > Alphabet Inc. (GOOGL.US) > Amazon.com, Inc. (AMZN.US) > Microsoft Corporation (MSFT.US).
~

AASTOCKS Financial News
Website: www.aastocks.com

MINIMAX-W (00100.HK)'s H3 model was open-sourced today (3rd). Huawei Ascend, MOORE THREADS (688795.SH), METAX (688802.SH), HYGON INFORMATION (688041.SH), Kunlunxin, ILUVATAR COREX (09903.HK), BIREN TECH (06082.HK), Advanced Micro Devices, Inc. (AMD.US), Intel Corporation (INTC.US), as well as Hugging Face, ModelScope and ComfyUI were among the 16-tier chipmakers, developer communities and cloud inference platforms that completed relevant compatibility support on the same day as the H3 open-source release.

MiniMax H3 is a general-purpose full-modality generation system. It ranks first globally in video editing capability on the Artificial Analysis leaderboard. The system can uniformly understand multimodal contexts comprising text, images, videos and audio, and can generate videos with up to 2K resolution, a maximum length of 15 seconds, and native stereo audio.

A relevant person in charge at MiniMax said the company will continue building more open, versatile and intelligent models, while working with partners to jointly foster a thriving open-source ecosystem.

MINIMAX-W leapfrogged 11.4% at one point to a peak of HKD256.8. It last reported at HKD247.6, up 7.37%, with trading volume of 6.3924 million shares, involving turnover of HKD1.582 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, Aug. 3, 2026 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) is pleased to announce today (Monday) the launch of its Five-Year China Government Bond (CGB) Futures contract, marking a significant step forward in the development of Hong Kong's fixed-income and currencies (FIC) ecosystem and further enriching the city's offshore Renminbi (RMB) market.

HKEX also warmly welcomes the measures announced by Wu Qing, Chairman of the China Securities Regulatory Commission, to deepen cooperation and connectivity between the Chinese Mainland and Hong Kong financial markets, and supporting the continued development of Hong Kong as an international financial centre.

HKEX held a launch ceremony at HKEX Connect Hall today, bringing together senior representatives from regulatory agencies, financial infrastructure institutions, market participants and industry stakeholders to celebrate the product launch.

For HKEX, the new CGB Futures contract expands its growing China-related product suite and complements existing mutual market access programmes, including Bond Connect and Swap Connect. As the only CGB futures contract available in the offshore market, this on-exchange listed instrument enhances investors' ability to manage duration and interest-rate exposure to the Chinese Mainland bond market.

HKEX Chairman, Carlson Tong, said: "A vibrant FIC market is critical to Hong Kong's future growth as an international financial centre. As global investors increase their participation in Asia's bond and RMB markets, Hong Kong has an important role to play as a trusted, open and connected hub that links China and the world. The launch of Five-Year China Government Bond Futures further strengthens Hong Kong's offshore RMB product suite, supports the continued internationalisation of the currency, and reinforces the city's position as a comprehensive platform for capital formation, trading and risk management."

HKEX Chief Executive Officer, Bonnie Y Chan, said: "We are delighted to see the launch of Five-Year China Government Bond Futures today, marking a key milestone as HKEX delivers on its strategic imperative to develop a more diversified, multi-asset marketplace. From Bond Connect and Swap Connect to our growing derivatives, commodities and FIC offerings, we are creating a more integrated ecosystem that enables investors to allocate capital, manage risk and access new opportunities. Looking ahead, we will be working closely with regulators, infrastructure partners and market participants to expand connectivity, broaden product choice and strengthen risk-management capabilities across asset classes."

The CGB Futures contract's pricing benchmark is supported by ChinaBond Pricing Center Co. Ltd., which licenses bond valuation data and provides price calculation services, enhancing transparency and credibility for offshore market participants.

The SFC Commission Levy will be exempted for the first six months of trading and a market-wide trading fee discount of 50 per cent will be applied until 30 July 2027. At launch, the contract is supported by 13 liquidity providers from banks and securities firms together with extensive market participants, reflecting strong industry engagement. More details about the Five-Year CGB Futures are available on the HKEX website.

About HKEX

Hong Kong Exchanges and Clearing Limited (HKEX) is a publicly-traded company (HKEX Stock Code: 388) and one of the world's leading global exchange groups, offering a range of equity, derivative, commodity, fixed income and other financial markets, products and services, including the London Metal Exchange.

As a superconnector and gateway between East and West, HKEX facilitates the two-way flow of capital, ideas and dialogue between China and the rest of the world, through its pioneering Connect schemes, increasingly diversified product ecosystem and its deep, liquid and international markets.

HKEX is a purpose-led organisation which, across its business and through the work of HKEX Foundation, seeks to connect, promote and progress its markets and the communities it supports for the prosperity of all.

www.hkexgroup.com 

At midday, the HSI concluded at 25,895, up 11 pts or 0.04%, with turnover at HKD142.699 billion. The HSTECH closed the half-day at 4,864, up 35 pts or 0.74%. The HSCEI stood at 8,622, up 10 pts or 0.13%.

Among active leading techs, BABA-W (09988.HK) elevated 6.75% after launching its Qwen 3.8-Max AI model, with performance comparable to Anthropic Fable. BIDU-SW (09888.HK) soared 3.87%. TENCENT (00700.HK) and KUAISHOU-W (01024.HK) rallied nearly 3%. JD-SW (09618.HK) and MEITUAN-W (03690.HK) advanced more than 1%. XIAOMI-W (01810.HK) cratered 3.68% by midday after announcing price hikes of up to RMB500 for its premium smartphone models. UBS trimmed its TP on the company, citing persistently high memory costs and weak end-market demand.

Among blue chips, XINYI SOLAR (00968.HK) was upgraded to Buy by Citi after its results announcement, with shares soaring 9.32%, making it the best-performing blue chip at midday. XINYI GLASS (00868.HK) rallied 2.36% after reporting a 17% increase in interim profit. HSBC HOLDINGS (00005.HK), which will announce results tomorrow, dipped 0.95%. SMIC (00981.HK) dropped 1.5%. CHINAHONGQIAO (01378.HK) slumped 6.52%, making it the worst-performing blue chip at midday. Macau's July GGR declined for a second consecutive month, sending SANDS CHINA LTD (01928.HK) and GALAXY ENT (00027.HK) down more than 2%.

Among AI-related stocks, MINIMAX-W (00100.HK) soared 8.07% after Citi praised the significant cost advantage of its H3 video model. Z.AI (02513.HK) lost 7.9%. XUNCE (03317.HK) swelled 14.3% after forecasting an interim turnaround to a profit of RMB72.51 million.
~

AASTOCKS Financial News
Website: www.aastocks.com

CXMT (688825.SH)'s sixth-generation low-power double data rate memory standard (LPDDR6) is nearing the end of its R&D validation stage, marking an important step before mass production, according to a report by China Business Network citing sources.

As early as March 2026, market sources divulged that CXMT was actively advancing the commercialization of LPDDR6 products and had already provided samples to core customers. The products are expected to be launched and enter mass production in 2H26.

In addition, SK hynix Inc. (SKHY.US) has recently finalized its LPDDR6 mass production plan, while XIAOMI-W (01810.HK) is expected to become one of the first manufacturers to adopt the memory in flagship smartphone models, report told.
~

AASTOCKS Financial News
Website: www.aastocks.com

Moonshot AI reached a computing power agreement with BABA-W (09988.HK), allowing it to use about 20,000 Nvidia (NVDA.US) chips, Bloomberg, citing sources, reported.

The chips reportedly obtained by Moonshot AI through BABA-W came from Nvidia's earlier-generation Hopper product, the H200 chip, although BABA-W denied the claim.

A spokesperson for BABA-W said reports that the company supplied H200 chips to Moonshot AI were completely groundless, but did not deny providing related Nvidia chip computing power to Moonshot AI, and also declined to disclose the actual chip model used.
~

AASTOCKS Financial News
Website: www.aastocks.com

CONCORD NE (00182.HK) gapped up 14.08% at the open today (3rd), reaching a peak of HKD0.415. It last printed at HKD0.395, up 11.27%, with turnover of HKD5.9297 million.

CONCORD NE announced that the Company’s wholly owned subsidiaries in the US entered into three long-term Power Purchase Agreements (PPAs) with Tesla (TSLA.US) for solar projects in the US.

The long-term PPAs cover three solar projects with a total capacity of approximately 469 MW (AC). Upon full operation of all three projects, the Company will supply Tesla with approximately 1,200 GWh of electricity annually in the US. The first project is expected to commence power supply in the first half of 2027.
~

AASTOCKS Financial News
Website: www.aastocks.com

The three major US stock indices finished up 0.5-1% last Friday (31st), driven by a more than 15% post-results surge in Amazon.com, Inc. (AMZN.US). Japan and the US confirmed their joint intervention in the foreign exchange market last Friday. Japan's stock market plummeted more than 1,600 points this morning (3rd), while South Korea's stock market also slumped more than 4%.

However, the HSI opened at 25,987, up 102 pts or 0.4%; the HSCEI opened at 8,659, up 46 pts or 0.55%; and the HSTECH opened at 4,861, up 32 pts or 0.68%.

Major techs edged higher broadly. BABA-W (09988.HK) opened up 3.42%; BIDU-SW (09888.HK) opened up 2.83%; while TENCENT (00700.HK) and KUAISHOU-W (01024.HK) opened more than 1% higher.

Automakers released July sales data. GEELY AUTO (00175.HK) opened up 1.52% after Zeekr brand sales more than doubled in July; BYD COMPANY (01211.HK)'s July NEV sales mounted nearly 22% YoY, with the stock opening nearly 1% higher; CHERY AUTO (09973.HK) opened up 2.7%; while LI AUTO-W (02015.HK) sank 1.22%.

Among individual stocks, XUNCE (03317.HK), which issued a positive profit alert, opened 14.98% higher; TAI HING GROUP (06811.HK) spiked 5.93% as the company expected interim profit to soar by more than 76%.
~

AASTOCKS Financial News
Website: www.aastocks.com

• 高管團隊重磅擴容將加碼全球商業化進程

中國蘇州2026年8月3日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）今日宣佈，公司任命Faical Miyara博士為首席業務拓展官（Chief Business Officer，CBO），負責亞盛醫藥的全球業務拓展工作；並任命Jim Ziegler為首席商務運營官（Chief Commercial Officer，CCO），負責公司產品在大中華地區以外的全球市場的商業化運營。Miyara博士和Ziegler先生直接向公司董事長兼首席執行官楊大俊博士匯報。

Miyara博士在全球大型製藥公司和生物技術公司中擁有超過20年的腫瘤領域商務拓展經驗。加入亞盛前，他曾任IO Biotech首席業務拓展官兼高管團隊核心成員；更早之前，他任職益普生副總裁，全面負責腫瘤領域全球商務合作，項目搜尋評估，以及風險投資機構關係管理工作。Miyara博士還曾在輝瑞公司任職五年，共同發起並建立了輝瑞紐約治療創新中心（CTI），並出任多個研發高級崗位；此後在ImClone公司與禮來公司任職五年，直接參與多項獲美國FDA批准的知名腫瘤生物制劑的研發、優化和開發，包括愛必妥^®（西妥昔單抗）與希冉擇^®（雷莫西尤單抗）。Miyara博士擁有法國巴黎皮埃爾與瑪麗・居裡大學（即索邦大學）的生殖生物學、分子生物學與細胞生物學的博士學位，以及法國格勒諾布爾約瑟夫・傅裡葉醫學院的醫學生物學碩士暨工程師學位。他始終深耕科研創新，曾參與撰寫多部學術專著章節，在多個同行評議科學期刊上發表過多篇論文，並作為主要發明人擁有三項獨立專利。

Ziegler先生是資深的生物醫藥行業高管，擁有超過25年的商業化運營及管理經驗。他曾主導多款產品的全球損益管控，搭建並規模化擴張高效能業務團隊，積累了覆蓋多款專科療法的產品上市及商業化全週期操盤經驗。Ziegler先生在商業化戰略制定、市場准入、組織體系搭建等領域積澱深厚，能夠主導推動腫瘤、血液疾病等複雜專科市場的跨職能協作與商業化落地。他兼具大型成熟藥企與新興生物製藥企業的商業化深厚從業經驗，曾先後任職於安進、吉利德科學等行業龍頭藥企，以及Lovance Biotherapeutics、Geron等新興生物藥企，並在後兩家企業領導全球商業化團隊。進入生物製藥行業前，Ziegler先生曾服役於美國陸軍，擔任裝甲軍官。他擁有美國西點軍校理學學士學位，以及芝加哥大學工商管理碩士學位。

楊大俊博士表示：「我們由衷歡迎Faical Miyara博士和Jim Ziegler先生加入公司高管團隊。隨著多項全球註冊III期臨床的快速推進，亞盛醫藥作為港股、納斯達克雙重主要上市的全球性創新藥企業，正邁向全球化佈局新階段。兩位資深高管的加入，將極大助力公司的全球業務拓展和全球商業化佈局。 

Miyara博士是一位極具創新精神和戰略遠見的領導者，在構建高價值腫瘤業務發展管線方面擁有卓越經驗。我們相信在Miyara博士的助力下，能更好地賦能公司的國際業務拓展。

Ziegler先生擁有豐富的專科療法從業經驗，尤其深耕血液腫瘤領域，在產品上市、市場准入與醫保報銷、商業化體系搭建及全球商業化戰略佈局方面都有豐富經驗。當前亞盛醫藥多款血液腫瘤產品正邁向全球商業化階段，Ziegler先生的經驗與公司全球化發展戰略高度契合，能夠顯著增強公司全球商業化能力，加速建立世界級商業化體系。

再次歡迎兩位的加入，我們期待與Miyara博士和Ziegler先生攜手，進一步夯實公司在全球血液腫瘤領域的領先地位，為全球患者帶來更多治療選擇。」

Faical Miyara博士表示：「我非常榮幸能加入亞盛醫藥。亞盛醫藥正在邁入全球化佈局推進的全新階段，我期待與這支優秀的團隊緊密攜手，依托過往積累的經驗，全力推動公司全球戰略落地與業務版圖拓展，與公司共攀發展新高度。」

Jim Ziegler先生表示：「我十分高興能見證並參與亞盛醫藥全球化發展的關鍵階段。亞盛醫藥現已打造具備差異化優勢的創新管線，有望解決血液腫瘤領域重大的未被滿足的臨床需求。我非常期待能攜手公司團隊共同推動公司全球商業化戰略與能力建設，更快地為全球患者提供更多重要的全新治療選擇。」

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球範圍內進行知識產權佈局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物製藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關係。如需瞭解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2026年4月29日提交的20-F表格中截止2025年12月31日的年度報告中的「風險因素」和「關於前瞻性聲明的警示聲明」章節，2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。